KEYTRUDA QLEX
KEYTRUDA QLEX is a combination of the PD-1 blocking antibody pembrolizumab and the endoglycosidase berahyaluronidase alfa. It is indicated for the treatment of adult and pediatric patients with various stages of melanoma, including unresectable, metastatic, and resected Stage IIB-III disease. The therapy is also approved for multiple non-small cell lung cancer (NSCLC) indications, ranging from neoadjuvant and adjuvant treatment of resectable tumors to first-line and subsequent therapy for metastatic disease. Depending on the specific condition, it may be administered as a single agent or in combination with platinum-based chemotherapy.
How KEYTRUDA QLEX Works
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with the ligands PD-L1 and PD-L2. This action releases the PD-1 pathway-mediated inhibition of the immune system, allowing for increased T cell proliferation and an active anti-tumor immune response. The second component, berahyaluronidase alfa, is an endoglycosidase that temporarily breaks down hyaluronan, a polysaccharide in the subcutaneous tissue's extracellular matrix. By depolymerizing hyaluronan, it increases the permeability of the subcutaneous tissue to facilitate drug delivery, an effect that is reversed within 24 to 48 hours.
Details
- Status
- Prescription
- First Approved
- 2025-09-19
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
KEYTRUDA QLEX Approval History
What KEYTRUDA QLEX Treats
2 indicationsKEYTRUDA QLEX is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Melanoma
- Non-Small Cell Lung Cancer
KEYTRUDA QLEX Target & Pathway
ProTarget
An immune checkpoint receptor on T-cells that acts as an 'off switch' for immune responses. Cancer cells often exploit PD-1 by expressing its ligands (PD-L1/PD-L2), allowing tumors to evade immune detection. Blocking PD-1 releases this brake, enabling T-cells to recognize and attack cancer cells.
Pathway Context
PD-1 on T-cells binds to PD-L1/PD-L2 on tumor cells, suppressing immune attack
A protein expressed on tumor cells and immune cells that binds to PD-1 on T-cells, suppressing immune responses. Many cancers overexpress PD-L1 to avoid immune attack. Blocking PD-L1 prevents this immune suppression, allowing the body's T-cells to fight cancer.
A second ligand for PD-1, expressed on antigen-presenting cells and some tumors. PD-L2 binds PD-1 with higher affinity than PD-L1 but is less widely expressed. Drugs blocking PD-1 prevent both PD-L1 and PD-L2 interactions.
KEYTRUDA QLEX Competitors
Pro10 other drugs also target PD-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PD-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to KEYTRUDA QLEX
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KEYTRUDA QLEX FDA Label Details
ProIndications & Usage
FDA Label (PDF)KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor ...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.